Enter your email address
Submit
Write your message
Volume 18, Issue 4 (Iranian Journal of Breast Diseases 2026)
ijbd 2026, 18(4): 88-101 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Budiono M B, Anita K W, Solimun S, Saputra A. Association of Mutant p53 Expression with Lymph Node Metastasis and Histological Grading in Breast Cancer Patients. ijbd 2026; 18 (4) :88-101
URL: http://ijbd.ir/article-1-1209-en.html
URL: http://ijbd.ir/article-1-1209-en.html
1- Department of Oncology Surgery, Dr. Saiful Anwar General Hospital – Brawijaya University, Malang, Indonesia
2- Department of Pathological Anatomy, Brawijaya University, Malang, Indonesia
3- Department of Statistics, Faculty of Mathematics and Natural Science, Brawijaya University, Malang, Indonesia
4- Department of Surgery, Brawijaya University – Dr. Saiful Anwar General Hospital, Malang, Indonesia ,apriandasaputra@gmail.com
2- Department of Pathological Anatomy, Brawijaya University, Malang, Indonesia
3- Department of Statistics, Faculty of Mathematics and Natural Science, Brawijaya University, Malang, Indonesia
4- Department of Surgery, Brawijaya University – Dr. Saiful Anwar General Hospital, Malang, Indonesia ,
Abstract: (278 Views)
Introduction: Breast cancer remains the most prevalent malignancy among women worldwide, with lymph node metastasis serving as a critical determinant of prognosis. Mutations in the TP53 gene, leading to the expression of dysfunctional p53 protein, have been implicated in tumor progression and nodal dissemination. This study aimed to analyze the association between mutant P53 expression and lymph node metastasis (LNM) as well as histopathological grading in breast cancer patients.
Methods: Retrospective cross-sectional study of 83 patients treated (Jan 2021–Dec 2024) at Dr. Saiful Anwar General Hospital, Indonesia. Mutant p53 was assessed by immunohistochemistry. Associations with LNM were tested by chi-square; correlations with grade by Spearman’s rho.
Results: The mean age of the subjects was 51.27 ± 10.24 years. Based on nodal staging, the majority of patients were classified as N1 (67.47%). Histopathological grading revealed Grade 3 as the most prevalent (53.0%). Statistical analysis demonstrated a significant association between mutant P53 expression and lymph node metastasis (p < 0.001; r = 0.670), indicating a strong positive correlation. In contrast, no significant association was observed between mutant P53 expression and histopathological grading (p = 0.485; r = 0.078).
Conclusion: Mutant p53 expression is strongly associated with lymph node metastasis but not with histological grade in breast cancer. Prospective studies incorporating advanced assessment methods are warranted to validate these findings.
Methods: Retrospective cross-sectional study of 83 patients treated (Jan 2021–Dec 2024) at Dr. Saiful Anwar General Hospital, Indonesia. Mutant p53 was assessed by immunohistochemistry. Associations with LNM were tested by chi-square; correlations with grade by Spearman’s rho.
Results: The mean age of the subjects was 51.27 ± 10.24 years. Based on nodal staging, the majority of patients were classified as N1 (67.47%). Histopathological grading revealed Grade 3 as the most prevalent (53.0%). Statistical analysis demonstrated a significant association between mutant P53 expression and lymph node metastasis (p < 0.001; r = 0.670), indicating a strong positive correlation. In contrast, no significant association was observed between mutant P53 expression and histopathological grading (p = 0.485; r = 0.078).
Conclusion: Mutant p53 expression is strongly associated with lymph node metastasis but not with histological grade in breast cancer. Prospective studies incorporating advanced assessment methods are warranted to validate these findings.
Type of Study: Research |
Subject:
molecular cell
Received: 2025/09/28 | Accepted: 2025/12/23 | Published: 2026/01/25
Received: 2025/09/28 | Accepted: 2025/12/23 | Published: 2026/01/25
References
1. Smolarz B, Nowak A, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022;14(10):2569. doi:10.3390/cancers14102569 [DOI:10.3390/cancers14102569] [PMID] []
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi:10.3322/caac.21834 [DOI:10.3322/caac.21834] [PMID]
3. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N. Breast cancer. Nat Rev Dis Prim. 2020;5(1):66. doi:10.1038/s41572-019-0111-2 [DOI:10.1038/s41572-019-0111-2] [PMID]
4. Zhang Y, Li J, Fan Y, Li X, Qiu J, Zhu M, et al. Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients. Medicine (Baltimore). 2019;98(40):e17481. doi:10.1097/md.0000000000017481 [DOI:10.1097/MD.0000000000017481] [PMID] []
5. Kalli S, Semine A, Cohen S, Naber S, Makim S, Bahl M. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. Radiographics. 2020;38(7):1921-33. doi:10.1148/rg.2020190067 [DOI:10.1148/rg.2018180056] [PMID]
6. Dooijeweert C van, Diest P van, Ellis I. Grading of invasive breast carcinoma: the way forward. Virchows Arch. 2022;480(1):33-43. doi:10.1007/s00428-021-03183-8 [DOI:10.1007/s00428-021-03141-2] [PMID] []
7. Marvalim C, Datta A, Lee S. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics. 2023;13(4):1421-42. doi:10.7150/thno.77532 [DOI:10.7150/thno.77532] [PMID] []
8. Freed-Pastor W, Prives C. Mutant p53: One name, many proteins. Genes Dev. 2022;36(15):881-902. doi:10.1101/gad.349665.122
9. Abubakar M, Guo C, Koka H, Sung H, Shao N, Guida J, et al. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. NPJ Breast Cancer. 2020;5(20). doi:10.1038/s41523-020-00151-4 [DOI:10.1038/s41523-019-0117-7] [PMID] []
10. Dash S, Sahu A, Toppo A. p53 Expression in Breast Carcinoma and Its Association with Tumor Aggressiveness. J Datta Meghe Inst Med Sci Univ. 2021;16(2):266-72.
11. Rana M, Rana A, Khera U. Expression of p53 and p16 in Carcinoma Breast Tissue: Depicts Prognostic Significance or Coincidence. Cureus. 2021;13(11):e19395. doi:10.7759/cureus.19395 [DOI:10.7759/cureus.19395]
12. Zhang F. Relationship between expression of p53 protein in breast cancer and axillary lymph node metastasis. Clin Surg Oncol. 2024;3(4):100067. doi:10.1016/j.cso.2024.100067 [DOI:10.1016/j.cson.2024.100067]
13. Zhang F. Relationship between p53 protein and ER, PR status in breast cancer tissue. Cancer Treat Res Commun. 2025;43(100895). doi:10.1016/j.ctarc.2025.100895 [DOI:10.1016/j.ctarc.2025.100895] [PMID]
14. Darling H. Basics of statistics - 4 : Sample size calculation ( ii ): A narrative review. Cancer Res Stat Treat. 2020;3(4):817-28. doi:10.4103/crst.crst_101_20 [DOI:10.4103/CRST.CRST_279_20]
15. Wihandani D, Wiryanthini ID, Yani M, Remitha NI, Sadvika IS, Indrakusuma A. Correlation of CD44 Protein Expression with Larger Tumor Size and Advanced Stage of Breast Cancer Patients. Asian Pacific J Cancer Prev. 2024;25(12):4175-80. doi:10.31557/apjcp.2024.25.12.4175 [DOI:10.31557/APJCP.2024.25.12.4175] [PMID] []
16. Tang Q, Su Z, Gu W, Rustgi A. Mutant p53 on the Path to Metastasis. Trends Cancer. 2020;6(1):62-73. doi:10.1016/j.trecan.2019.11.006 [DOI:10.1016/j.trecan.2019.11.006] [PMID] []
17. Chen Y, Horigome E, Fujieda M, Handa T, Katayama A, Ito M, et al. Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. Oncotarget. 2022;9(77):34554-66. doi:10.18632/oncotarget.25984 [DOI:10.18632/oncotarget.25984] [PMID] []
18. Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2022;23(12):6806. doi:10.3390/ijms23126806 [DOI:10.3390/ijms23126806] [PMID] []
19. Noguchi M, Kitagawa H, Kinoshita K, Thomas M, Miyazaki I, Saito Y, et al. The relationship of p53 protein and lymph node metastases in invasive breast cancer. Surg Today. 1994;24(6):512-7. doi:10.1007/bf00311841 [DOI:10.1007/BF00311841]
20. Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLoS One. 2017;24(12):e0172324. doi:10.1371/journal.pone.0172324 [DOI:10.1371/journal.pone.0172324] [PMID] []
21. Ding L, Zhang Z, Xu Y, Zhang Y. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered. 2017;8(4):383-92. doi:10.1080/21655979.2017.1284725 [DOI:10.1080/21655979.2016.1235101] [PMID] []
22. Salih M, Higgo A, Eed E. Prognostic Significance of p16 Protein Expression in Breast Cancer. In Vivo. 2022;36(1):336-40. doi:10.21873/invivo.12809 [DOI:10.21873/invivo.12809] [PMID] []
23. Zhu G, Pan C, Bei J, Li B, Liang C, Xu Y, et al. Mutant p53 in Cancer Progression and Targeted Therapies. Front Oncol. 2020;10:595187. doi:10.3389/fonc.2020.595187 [DOI:10.3389/fonc.2020.595187] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
